Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
236 Leser
Artikel bewerten:
(1)

India's leading healthcare network Manipal Hospitals welcomes India's leading cancer specialist Dr. Surender Kumar Dabas to strengthen robotic cancer care in Delhi NCR

NEW DELHI, Aug. 18, 2025 /PRNewswire/ -- Manipal Hospitals, one of India's leading and globally recognized healthcare institutions, welcomes one of India's most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas as Chairman - Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster. With this addition, the hospital across Delhi, Gurugram and Ghaziabad further reinforces its vision to be a destination for world-class cancer care, catering to patients across India as well as international geographies.

Dr. Surender Kumar Dabas, Chairman - Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster

Dr. Surender Dabas brings with him more than 22 years of experience in surgical oncology and has been a pioneer in the field of robotic head and neck cancer surgery. Over the years, he has performed over 30,000 cancer surgeries, including more than 4,000 robot-assisted procedures, making him one of the most experienced robotic oncosurgeons in India. His expertise spans robot-assisted surgeries for head and neck cancer, thoracic cancer, gynaecologic malignancies, urological cancer, gastrointestinal and colorectal cancer, and breast cancer.

Welcoming the doctor, Mr. Pramod Alagharu, Regional COO North-West Cluster, Manipal Hospitals, said, "We are proud to welcome Dr. Surender Dabas and his strong team of 150 medical experts. With his specialized expertise in managing complex cancer procedures, Dr. Dabas brings immense value to our commitment to delivering world-class healthcare, including robot-assisted cancer treatment. His leadership will strengthen our role as a preferred destination for complex oncology cases for both domestic and international patients."

Speaking about his new role, Dr. Surender Kumar Dabas, Chairman - Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster added, "I am excited to join the Manipal family, one of the largest healthcare networks in India, which has a long-standing reputation for excellence in healthcare. My goal is to build on a strong foundation here and bring the most advanced and precise cancer care to both national and international patients. Through the use of robotics and newer technologies, we aim to make surgeries safer, less invasive, and more effective, improving both survival and quality of life for our patients."

With Dr. Dabas leading the Manipal Comprehensive Cancer Centre, the hospital is poised to emerge as a centre of excellence in comprehensive cancer care, offering advanced clinical protocols, evidence-based treatment, and a multidisciplinary approach to managing cancer. This will further position Manipal Hospitals as a trusted partner for international patients seeking high-quality, technology-led cancer treatment in India.

For any inquiries, contact our team at query.mhd@manipalhospitals.com or call us +91 8527388881.

About Manipal Hospitals

As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 38 hospitals across 19 cities with 10,500+ beds and a talented pool of 7,200+ doctors and an employee strength of over 20,500.

Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.

Photo: https://mma.prnewswire.com/media/2752276/Dr__SK_Dabas_Manipal_Hospitals.jpg
Logo: https://mma.prnewswire.com/media/1941277/Manipal_Hospital_Logo.jpg

Manipal Hospital Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/indias-leading-healthcare-network-manipal-hospitals-welcomes-indias-leading-cancer-specialist-dr-surender-kumar-dabas-to-strengthen-robotic-cancer-care-in-delhi-ncr-302532129.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.